Picture Demy-Colton BioFuture 2024 NYC 3 Biotech Breakthroughs 650x100px
Financing › Details

Exolvo Biosciences–NLC Ventures: investment, 202406 investment NLC will launch Exolvo as spin-off from Verily


Period Period 2024-06-24
Organisations Money taker Exolvo Biosciences (US)
  Money source NLC Ventures Netherlands B.V. (NLC Health Ventures)
  Group NLC Ventures (Group)
Products Product oral drug delivery technology for biologics
  Product 2 venture capital
Person Person Ibery, Nick (NLC Ventures 202406 Lead Partner UK + Ireland)

NLC Ventures Netherlands B.V.. (6/24/24). "Press Release: NLC Health Ventures Launches New Early-stage Drug Delivery Company".

NLC Health Ventures, in collaboration with Verily, a precision health technology company, will launch Exolvo Biosciences, a pioneering biotech company delivering the next-generation solution for biologic drug delivery.

Through Exolvo, NLC seeks to advance drug delivery technology that was incubated within Verily and is now being spun out as a stand-alone private early-stage venture under NLC. Exolvo will benefit from NLC’s venture-building approach and its extensive ecosystem of health experts and industry partnerships. Exolvo’s oral drug delivery technology is distinguished by its flexible capsule size and modular design, allowing adaptation to a variety of large molecular structures. This flexibility and modularity are key differentiators, setting Exolvo apart in the industry and positioning it at the forefront of oral drug delivery innovation.

“This technology has tremendous potential for significant impact. For patients, it means an improved and better treatment experience, and for healthcare workers, it simplifies administration and enhances efficiency in delivering care,” said Nick Ibery, UK Lead Partner at NLC.


Biologic drugs are essential for treating various chronic conditions, such as autoimmune diseases, cancer, and cardiometabolic diseases including diabetes and obesity. Due to their larger size and complexity, biologics are sensitive to the digestive enzymes and acidic environment of the gastrointestinal tract, making oral delivery challenging. As a result, biologic drugs are usually administered through frequent and painful needle injections or intravenous administration. Such treatments can be burdensome for patients and costly for healthcare systems.

“Talk to anyone living with a chronic disease like diabetes and they will mention the struggle of having to inject themselves – in some cases – even multiple times a day. There is a need for innovative solutions that can make treatments more accessible and less invasive for people that live with chronic conditions,“ says Exolvo co-founder and CEO, Brian Longstreet, who brings extensive experience from the pharma and biotech industry.

Exolvo’s technology is progressing towards assembling an IND package in the U.S., while simultaneously actively engaging with key pharmaceutical and biotech partners.

About Exolvo Biosciences

Exolvo Biosciences is an innovative biotech company leading the way in transforming the oral delivery of large, complex molecules. Applying technology incubated within Verily, Exolvo is committed to revolutionizing biologic drug delivery, making treatments more accessible and less invasive for patients. With a focus on pioneering solutions in an area that has seen limited advancements, Exolvo aims to improve patient outcomes and healthcare efficiency globally.

Record changed: 2024-07-02


Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x200px

More documents for Exolvo Biosciences (US)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Demy-Colton BioFuture 2024 NYC Game Changers 650x300px

» top